N-Acetylglycine

CAS No. 543-24-8

N-Acetylglycine ( Aceturic acid;Acetamidoacetic acid )

Catalog No. M19625 CAS No. 543-24-8

N-Acetylglycine is a minor constituent of numerous foods with no genotoxicity or acute toxicity. N-acetylglycine is used in biological research of peptidomimetics.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG 37 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    N-Acetylglycine
  • Note
    Research use only not for human use.
  • Brief Description
    N-Acetylglycine is a minor constituent of numerous foods with no genotoxicity or acute toxicity. N-acetylglycine is used in biological research of peptidomimetics.
  • Description
    N-Acetylglycine is a minor constituent of numerous foods with no genotoxicity or acute toxicity. N-acetylglycine is used in biological research of peptidomimetics.
  • Synonyms
    Aceturic acid;Acetamidoacetic acid
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    543-24-8
  • Formula Weight
    117.1
  • Molecular Formula
    C4H7NO3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM;Water: 27 mg/mL
  • SMILES
    CC(=O)NCC(O)=O
  • Chemical Name
    Glycine N-acetyl-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Harper MS et al. Toxicology studies with N-acetylglycine. Food Chem Toxicol. 2010 May;48(5):1321-7.
molnova catalog
related products
  • 6-(4-Hydroxy-3-methy...

    6-(4-Hydroxy-3-methylphenyl)-2-methylhept-2-en-4-one is a natural product for research related to life sciences.

  • Ac-IEPD-AFC

    Ac-IEPD-AFC (IEPD) is a substrate of Granzyme B.

  • BV02

    BV02 is an inhibitor of 14-3-3 protein-protein interactions and can be used in studies about the treatment of chronic myeloid leukemia. BV02 disrupts hematopoietic cells expressing the IM-resistant T315I mutation and the IM-sensitive wild-type Bcr-Abl.